Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Menon

Showing results (431-440 of 510) with videos related to

Pageof 51
Sort By:
Hematological Oncology|December 17, 2016
Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergyKevin J Freise, Aksana K Jones, Rajeev M Menon, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|January 24, 2024
Progressive vascular tumor in infant: A case report and literature review of PIK3CA vascular malformationAllison Medina, Laura Zima, Autumn Atkinson, et al.
British Journal of Clinical Pharmacology|October 19, 2023
Venetoclax pharmacokinetics in participants with end-stage renal disease undergoing haemodialysisBehnam Noorani, Rajeev M Menon, Xin Chen, et al.
European Journal of Clinical Pharmacology|October 7, 2018
Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trialsDiana L Shuster, Rajeev M Menon, Bifeng Ding, et al.
International Journal of Molecular Sciences|November 9, 2024
Epigenetic Mechanisms Induced by <i>Mycobacterium tuberculosis</i> to Promote Its Survival in the HostShwetha Susan Thomas, Kuniyil Abhinand, Arjun M Menon, et al.
The AAPS Journal|November 25, 2015
Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 StudiesSven Mensing, Akshanth R Polepally, Denise König, et al.
Nature Communications|April 17, 2014
Visualization of exciton transport in ordered and disordered molecular solidsGleb M Akselrod, Parag B Deotare, Nicholas J Thompson, et al.
Nano Letters|July 16, 2016
Broadband Enhancement of Spontaneous Emission in Two-Dimensional Semiconductors Using Photonic HypercrystalsTal Galfsky, Zheng Sun, Christopher R Considine, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 1, 1989
Radiosensitivity of human prostate cancer and malignant melanoma cell linesM Wollin, T J FitzGerald, M A Santucci, et al.
British Journal of Clinical Pharmacology|September 24, 2016
Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trialsSven Mensing, Doerthe Eckert, Shringi Sharma, et al.
Pageof 51

Showing results (431-440 of 510) with videos related to

Sort By:
Pageof 51
Hematological Oncology|December 17, 2016
Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergyKevin J Freise, Aksana K Jones, Rajeev M Menon, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|January 24, 2024
Progressive vascular tumor in infant: A case report and literature review of PIK3CA vascular malformationAllison Medina, Laura Zima, Autumn Atkinson, et al.
British Journal of Clinical Pharmacology|October 19, 2023
Venetoclax pharmacokinetics in participants with end-stage renal disease undergoing haemodialysisBehnam Noorani, Rajeev M Menon, Xin Chen, et al.
European Journal of Clinical Pharmacology|October 7, 2018
Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trialsDiana L Shuster, Rajeev M Menon, Bifeng Ding, et al.
International Journal of Molecular Sciences|November 9, 2024
Epigenetic Mechanisms Induced by <i>Mycobacterium tuberculosis</i> to Promote Its Survival in the HostShwetha Susan Thomas, Kuniyil Abhinand, Arjun M Menon, et al.
The AAPS Journal|November 25, 2015
Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 StudiesSven Mensing, Akshanth R Polepally, Denise König, et al.
Nature Communications|April 17, 2014
Visualization of exciton transport in ordered and disordered molecular solidsGleb M Akselrod, Parag B Deotare, Nicholas J Thompson, et al.
Nano Letters|July 16, 2016
Broadband Enhancement of Spontaneous Emission in Two-Dimensional Semiconductors Using Photonic HypercrystalsTal Galfsky, Zheng Sun, Christopher R Considine, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 1, 1989
Radiosensitivity of human prostate cancer and malignant melanoma cell linesM Wollin, T J FitzGerald, M A Santucci, et al.
British Journal of Clinical Pharmacology|September 24, 2016
Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trialsSven Mensing, Doerthe Eckert, Shringi Sharma, et al.
Pageof 51